CADTH

CADTH
Name	Canadian Agency for Drugs and Technologies in Health
Formation	1989 (as Canadian Coordinating Office for Health Technology Assessment); 2006 (restructured)
Headquarters	Ottawa, Ontario
Region served	Canada
Leader title	President and CEO

CADTH

CADTH is an independent, not-for-profit organization that provides evidence-based health technology assessment to inform decision-making by provincial, territorial, and federal health ministries of Canada and public payers. It produces systematic reviews, health technology assessments, and reimbursement recommendations concerning pharmaceutical drugs, medical devices, and clinical procedures to support policy decisions across Ontario, British Columbia, Quebec, Alberta, Nova Scotia, and other jurisdictions. CADTH’s outputs are used alongside guidance from bodies such as Health Canada, Canadian Institutes of Health Research, Institut national d'excellence en santé et en services sociaux, and international counterparts like the National Institute for Health and Care Excellence, Institute for Clinical and Economic Review, and Australian Government Department of Health.

Overview

CADTH conducts comparative effectiveness research and economic evaluations to inform formulary listings, procurement, and clinical practice guidance. Its products include the Common Drug Review (historical), the Canadian Drug Expert Review Committee reports, the pan-Canadian Pharmaceutical Alliance analyses, and the health technology assessments used by agencies such as Public Health Agency of Canada, Canadian Agency for Drugs and Technologies in Health stakeholders. CADTH engages with clinical experts from institutions like University of Toronto, McGill University, University of British Columbia, and Université de Montréal and collaborates with international partners including European Medicines Agency, World Health Organization, and the Organisation for Economic Co-operation and Development.

History and Mandate

Originating as the Canadian Coordinating Office for Health Technology Assessment in 1989, the agency evolved amid federal-provincial discussions involving actors such as the Royal College of Physicians and Surgeons of Canada and the Canadian Medical Association to address variation in access to technologies. Legislative and policy frameworks—referencing decisions by Supreme Court of Canada and federal funding mechanisms shaped by precedents like the Canada Health Act—influenced its remit. Through restructuring in the 2000s, CADTH’s mandate expanded to include rapid reviews, health economics, and real-world evidence synthesis to support payers and decision-makers in provinces including Saskatchewan and Newfoundland and Labrador as well as territorial authorities in Yukon, Northwest Territories, and Nunavut.

Organizational Structure and Governance

CADTH is governed by a board of directors with representation from provincial and territorial health authorities and academic stakeholders such as McMaster University and Dalhousie University. Its advisory committees have included clinicians and patient representatives drawn from networks like the Canadian Patient Safety Institute and disease-specific organizations including Canadian Cancer Society and Heart and Stroke Foundation of Canada. Senior leadership liaises with procurement agencies such as the pan-Canadian Pharmaceutical Alliance and regulatory bodies including Health Canada. Accountability mechanisms involve reporting relationships analogous to those used by Crown corporations and arms-length agencies in provinces such as Ontario, with governance practices influenced by models from NHS England and the Canadian Food Inspection Agency.

Health Technology Assessment Activities

CADTH performs systematic literature reviews, network meta-analyses, budget impact models, and cost-effectiveness analyses to evaluate interventions ranging from oncology drugs reviewed alongside groups like Canadian Partnership Against Cancer to devices assessed in collaboration with Canadian Agency for Drugs and Technologies in Health stakeholders. It issues Rapid Response Reports, Common Drug Reviews (historical), and Therapeutic Review outputs used by formulary decision-makers in provinces such as Manitoba and Prince Edward Island. CADTH also operates health technology assessment methodologies aligned with standards from Cochrane Collaboration and reporting frameworks like the PRISMA Statement. It integrates stakeholder input from patient advocacy groups such as Alzheimer Society of Canada and clinician networks associated with Canadian Medical Association to contextualize clinical and economic evidence.

Impact and Influence on Canadian Healthcare Policy

CADTH’s assessments have influenced drug reimbursement decisions, negotiated pricing via the pan-Canadian Pharmaceutical Alliance, and provincial formulary listings that affect access to therapies for conditions addressed by organizations like Canadian Cancer Society and Crohn's and Colitis Canada. Its evidence has been cited in provincial policy documents produced by ministries in Ontario and Quebec and in national strategies coordinated with Health Canada and the Public Health Agency of Canada. Internationally, CADTH outputs contribute to cross-jurisdictional comparisons alongside bodies such as NICE and the Therapeutic Goods Administration (Australia), informing procurement strategies and value-based pricing debates in countries including United Kingdom and Australia.

Criticisms and Controversies

CADTH has faced critiques regarding transparency, timeliness, and the weighting of real-world evidence versus randomized controlled trials by stakeholders including patient groups like Canadian Cancer Society and industry bodies such as Innovative Medicines Canada. Controversies have arisen over past recommendation reversals and the perceived influence of provincial budgetary constraints on assessment outcomes, with commentary from academic centres including University of British Columbia and think tanks like the Fraser Institute. Debates continue about patient engagement practices and about methodological choices in cost-effectiveness thresholds analogous to disputes seen with NICE and Institute for Clinical and Economic Review.

Category:Health technology assessment organizations in Canada